Who is sponsoring NCT05719103?

NCT05719103 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT05719103?

Interventions in NCT05719103: With and Without Awake Prone Positioning.

What condition does NCT05719103 study?

NCT05719103 studies Respiratory Distress Syndrome, Ventilation Therapy; Complications.

Is NCT05719103 still recruiting?

NCT05719103 is currently status unknown. Last updated 9 May 2023.

Last reviewed 2023-05-09 · How we verify

NCT05719103

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Changes in Lung Aeration and Inspiratory Effort With and Without Awake Prone

Status unknown NA Last updated 9 May 2023

What this trial tests

NA trial testing With and Without Awake Prone Positioning in Respiratory Distress Syndrome in 34 participants. Status unknown.

Timeline

9 January 2023

Primary endpoint
31 December 2023

31 December 2025

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	9 January 2023
Primary completion	31 December 2023
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

With and Without Awake Prone Positioning

Conditions studied

Respiratory Distress Syndrome — all drugs for Respiratory Distress Syndrome →
Ventilation Therapy; Complications — all drugs for Ventilation Therapy; Complications →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 90, any sex, with Respiratory Distress Syndrome or Ventilation Therapy; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aimed to investigate the ventilation homogeneity and transpulmonary pressure during treatments of High-flow nasal cannula(HFNC) and (CPAP) on supine and prone position for COVID-19 or non-COVID-19 patients with acute hypoxemic respiratory failure (AHRF).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prone Positioning for Patients With COVID-19-Induced Acute Hypoxemic Respiratory Failure: Flipping the Script.
Li J, Ibarra-Estrada M, Guérin C. · · 2023 · cited 1× · PMID 37722733 · DOI 10.4187/respcare.11227

Verify or expand the search:

Other recruiting trials for Respiratory Distress Syndrome

Currently open trials in the same condition.

NCT07437391 — Effect of L-Carnitine Supplementation in Preterm Neonates · NA · recruiting
NCT06807983 — LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly · NA · recruiting
NCT07154134 — Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06430554 — Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability · recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05719103 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 9 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05719103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing